Operates multi-specialty hospitals under the Medanta brand, providing inpatient and outpatient clinical care across facilities in India. As of March 31, 2026, the network runs 6 hospitals with 3,665 installed beds, with 5 additional hospitals in the pipeline. Revenue is generated from patient services — hospitalisation, surgeries, consultations and diagnostics — and is split between mature hospitals (such as the Gurugram flagship) and developing units (Lucknow, Patna, Noida). In Q1 FY26, mature hospitals delivered total income of ₹7,006 mn at 23.4% EBITDA margin, while developing hospitals (Lucknow, Patna) delivered ₹3,219 mn at 29.3% margin with 64% occupancy. International patient revenue from CIS, Africa and Southeast Asia rebounded 34% YoY in Q1 FY26. The group has a 2,000-bed expansion pipeline over 3-4 years, including a 550-bed Noida hospital (opened November 2025), a 110-bed Ranchi unit (July 2025) and a Guwahati hospital scaled up to 650 beds, with FY27 capex guided at ₹800-900 crore. Employee expenses (24.9% of revenue) and materials consumed (20.0% of revenue) are the largest cost lines. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Mature hospitals, Developing hospitals, International patient revenue. Asset-heavy multi-specialty hospital network in expansion mode
| ₹ crore · consolidated | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 2,694 | 3,275 | 3,692 | 4,410 |
| EBITDA (ex other income) | 612 | 799 | 827 | 918 |
| margin % | 22.7 | 24.4 | 22.4 | 20.8 |
| Owners' profit | 326 | 478 | 481 | 556 |
| EPS, as reported (₹) | 12.58 | 17.80 | 17.92 | 20.71 |
| ROE % · ROCE % | 13.4 · 14.9 | 16.5 · 19.0 | 14.2 · 17.2 | 13.9 · 15.0 |
| Debt / equity (x) | 0.35 | 0.14 | 0.10 | 0.30 |
| Cash from operations | 645 | 612 | 624 | 714 |
| Capex | (236) | (279) | (517) | (838) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 |
| Profit before tax | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 |
| Net profit | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 |
| EPS (₹) | 4.87 | 5.32 | 3.77 | 5.92 | 5.89 | 3.54 | 5.36 | 5.91 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Medanta schedules analyst and investor meetings on Sep 17 and 18 | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Medanta schedules investor meetings with Jefferies and Kotak on Sept 17-18 | board shareholder meetings | low | — | — |
| 10 Sept 2026 · Medanta to meet analysts on Sept 15 in Noida | board shareholder meetings | low | — | — |
| 9 Sept 2026 · Medanta to meet investors and analysts in Lucknow on September 14 | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Medanta schedules analyst meets with Polar Capital and Chikara | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Medanta schedules investor meetings with Polar Capital and Chikara | board shareholder meetings | low | — | — |
| 31 Aug 2026 · Medanta schedules one-on-one investor meetings on September 8, 2026 | board shareholder meetings | low | — | — |
| 25 Aug 2026 · Medanta schedules investor and analyst meeting on Aug 31, 2026 in Noida | board shareholder meetings | low | — | — |
| 22 Aug 2026 · Medanta to meet Motilal Oswal analysts on Aug 26 and 27, 2026 | board shareholder meetings | low | — | — |
| 22 Aug 2026 · Medanta schedules investor meetings with Motilal Oswal | investor communications | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| (11.6) |
| 14.3 |
| GLOBAL HEALTH LIMITED ◆ | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 | 5.1 | 24.0 | 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 | — | 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 70.0 | 47.3 | 25 of 30 | 17% |
| P/B | 9.8 | 6.2 | 21 of 24 | 13% |
| ROCE | 13.6 | 10.9 | 10 of 30 | 69% |
| ROE | 13.9 | 11.8 | 8 of 24 | 70% |
| Debt / Equity | 0.3 | 0.2 | 16 of 24 | 35% |
| EBITDA margin | 23.7 | 22.0 | 11 of 24 | 57% |
| Revenue growth | 26.5 | 20.2 | 7 of 23 | 73% |
| Profit growth | (1.1) | 8.1 | 17 of 21 | 20% |
| Market cap | 38972 | 2415 | 5 of 30 | 86% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
